Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT02174939

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02174939
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02174939. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2017-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease
Intervention (Drug)
Cilostazol
Intervention (Drug)
Dummy Placebo
Lead sponsor
National Cheng-Kung University Hospital (class: other)
Collaborator
Department of Health, Executive Yuan, R.O.C. (Taiwan) (class: other government)

Record details

Record id
cardio:ct-nct02174939
Content hash
3f3e8122381f806204c0dceda120b0511f8c2b8e32bf1d9f421ca3751f1da4cd